asxan.ai Agents Hub

Heart Health

Evidence Stack

Cardiovascular support · lipid · vascular function

Evidence-first cardiovascular support stack — what the human-evidence record actually shows for the ingredients most associated with heart health, including the conditional omega-3 story and the null trials. This is mechanism and evidence mapping, not medical advice. Cardiovascular conditions require physician-led management; discuss any cardiovascular supplementation with your prescribing physician. All PubMed identifiers are verified against PubMed before inclusion; cross-market regulatory claims appear verbatim per their authorising authority (FDA · EFSA · ANVISA · TGA).

Last reviewed · How we assess evidence →

Quick Summary

  • Omega-3 cardiovascular outcomes are conditional, not universal. REDUCE-IT (PMID 30415628) found 4 g/day pure prescription EPA reduced major cardiovascular events by 25% in statin-treated adults with elevated triglycerides and prior CV disease or diabetes plus risk factors. VITAL (PMID 30415637) found 1 g/day combined EPA+DHA did not reduce total major CV events in a general adult primary-prevention population. STRENGTH (PMID 33190147) found 4 g/day EPA+DHA carboxylic-acid did not reduce events and increased atrial fibrillation risk. Dose, form, EPA-to-DHA ratio, and baseline risk all matter — read all three trials together. See /ingredients/omega-3/, EPA, and DHA.
  • Triglyceride lowering is well-established. EPA+DHA at 2 to 4 g/day reduces serum triglycerides by 15 to 30% across meta-analyses (PMID 37264945), independent of the event-prevention question.
  • Astaxanthin cardiovascular signals are moderate / mixed. Xia 2020 meta-analysis (PMID 32755613) reported significant HDL-C improvement and partial blood-pressure signals; BMI/body-weight not significant; CAD primary endpoints largely non-significant in Heidari 2023 RCT (PMID 37051124).
  • CoQ10 and Vitamin K2 are scientifically interesting but the cardiovascular evidence here is preliminary / emerging.
  • This is not medical advice. Cardiovascular conditions require physician-led management. The stack below is mechanism and evidence mapping — discuss any cardiovascular supplementation with your prescribing physician.

The Evidence Stack

The "evidence" column below describes the strength and direction of the outcome evidence in qualitative terms — well-established, robust, moderate/mixed, preliminary/emerging, or null/negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

Ingredient Cardiovascular evidence (qualitative) Key Trial / Meta-analysis asxan.ai page
Omega-3 (EPA / DHA) Well-established for triglyceride lowering; conditional / mixed for CV outcomes (REDUCE-IT positive; VITAL & STRENGTH null, with an atrial-fibrillation signal at 4 g/day) REDUCE-IT PMID 30415628 (4 g/day EPA, statin + TG ≥135); VITAL PMID 30415637 (1 g/day mixed, null primary); STRENGTH PMID 33190147 (4 g/day, AF safety signal); TG meta PMID 37264945 /ingredients/omega-3/ · EPA · DHA
Astaxanthin Moderate / mixed — partial lipid and blood-pressure signals; CAD primary endpoints largely null Xia 2020 PMID 32755613 (CV meta · HDL-C significant · BMI null); Heidari 2023 PMID 37051124 (CAD RCT · TC significant · TNF-α / SIRT1 null); Gonzalez 2024 PMID 39568140 (firefighter crossover · mixed) /ingredients/astaxanthin/
CoQ10 Preliminary / emerging — heart-failure-specific signal (Q-SYMBIO) in chronic heart failure, not general-population prevention Q-SYMBIO PMID 25282031 (heart-failure adjunctive · MACE composite reduced) /ingredients/coq10/
Vitamin K2 Preliminary / emerging — calcium-routing mechanism plausible; clinical-endpoint translation debated Matrix Gla-protein carboxylation mechanism · clinical-endpoint translation debated /ingredients/vitamin-k2/

How It Works

Each ingredient engages cardiovascular biology by a different route — omega-3 through membrane composition, eicosanoid balance, and hepatic VLDL reduction; astaxanthin as a mitochondrial-membrane antioxidant; CoQ10 in the electron transport chain; vitamin K2 through matrix Gla-protein calcium routing.

EPA and DHA — membrane composition, eicosanoid balance, triglyceride metabolism. EPA and DHA incorporate into membrane phospholipids, shift the eicosanoid balance toward less-inflammatory derivatives (resolvins, protectins), reduce hepatic VLDL secretion (the mechanistic basis for triglyceride lowering), and have modest blood-pressure and platelet-aggregation effects. The cornerstone REDUCE-IT result with pure EPA suggests that EPA-specific effects (independent of DHA) may carry much of the cardiovascular signal in high-risk statin-treated populations. See /ingredients/omega-3/#mechanism for the full mechanism narrative, and the standalone EPA (fish-first; conditional CV) and DHA (algae first-line; structural) monomer pages.

Astaxanthin — mitochondrial-membrane antioxidant, partial lipid modulation. Astaxanthin's xanthophyll structure spans the mitochondrial inner membrane; in the cardiovascular context, the Xia 2020 meta-analysis reported significant HDL-C improvements and partial blood-pressure signals (PMID 32755613), with the most robust signal in HDL-C rather than LDL-C or total cardiovascular events. CAD primary endpoints in dedicated RCTs were largely non-significant (Heidari 2023 PMID 37051124).

CoQ10 — mitochondrial electron-transport-chain coenzyme. CoQ10 (ubiquinone / ubiquinol) is a mitochondrial coenzyme essential for ATP synthesis and a co-antioxidant within the inner mitochondrial membrane. The cardiology literature includes Q-SYMBIO (heart failure) and statin-myopathy contexts. Treat the mechanism as biochemically plausible, with the strongest evidence confined to the heart-failure-specific Q-SYMBIO cohort.

Vitamin K2 — calcium routing. Vitamin K2 (menaquinone) is a cofactor for matrix Gla-protein (MGP) carboxylation. Activated MGP inhibits vascular calcification; the mechanistic logic is that adequate K2 status routes circulating calcium to bone rather than arterial wall. Clinical-endpoint translation is debated.

Omega-3 dose-response on lipid endpoints (mechanism anchor). The Wang 2023 dose-response meta (PMID 37264945) is the cleanest single source for the EPA+DHA dose-effect curve on serum triglycerides, total cholesterol, and LDL-C — confirming that the triglyceride-lowering effect is consistent and dose-dependent (15 to 30% at 2 to 4 g/day) and is mechanistically independent of the event-prevention question that REDUCE-IT, VITAL, and STRENGTH disagree on.

CoQ10 in chronic heart failure — Q-SYMBIO trial. The Q-SYMBIO trial (Mortensen 2014 PMID 25282031, JACC Heart Fail) randomized 420 patients with moderate-to-severe chronic heart failure to 100 mg of ubiquinone three times daily vs placebo as adjunctive to standard heart-failure therapy. At 2 years, the primary composite endpoint (major adverse cardiovascular events) was reduced; the trial is a key piece of the CoQ10 cardiology literature alongside the contested statin-myopathy context. This single Q-SYMBIO citation is included here as the named heart-failure-specific trial context, not as a generalized cardiovascular-prevention claim.

Fiber and cardiometabolic endpoints (cross-link cluster). The Reynolds 2019 Lancet systematic review (PMID 30638909) pooled prospective and trial evidence for dietary fiber and cardiometabolic outcomes; Jovanovski 2018 (PMID 30239559) is the psyllium LDL-C meta (~0.33 mmol/L reduction at ~10.2 g/day). These dietary-pattern-level anchors are relevant adjacent context for the cardiovascular supplementation discussion — the supportable framing is that fiber-adequate dietary patterns contribute to baseline cardiometabolic risk, on top of which the omega-3 dose-and-form question operates.

Body systems engaged: Cardiovascular. Mechanism tags: Nitric oxide (NO) pathway · NF-κB signaling inhibition · Free radical scavenging.

What the Trials Show — Including the Nulls

Astaxanthin negative findings. The Heidari 2023 CAD RCT (PMID 37051124, n=50, 12 mg/day for 8 weeks) reported significant total cholesterol reduction but non-significant effects on body composition, glycemic parameters, TNF-α, and SIRT1. The Gonzalez 2024 firefighter crossover RCT (PMID 39568140, n=15, 12 mg/day for 4 weeks) reported non-significant fasting oxidative, blood-lipid, and tactical-task outcomes.

CoQ10 and K2. Do not assume the popular cardiology positioning of CoQ10 (statin myopathy, heart failure) or K2 (vascular calcification) maps to high-quality meta-analytic evidence; outside the heart-failure-specific Q-SYMBIO cohort, the cardiovascular evidence remains preliminary / emerging.

Q-SYMBIO is a heart-failure trial, not a general-population cardiovascular-prevention trial. The Mortensen 2014 Q-SYMBIO trial (PMID 25282031) recruited patients with diagnosed moderate-to-severe chronic heart failure receiving guideline-directed therapy. The benefit on the composite endpoint was observed as adjunctive therapy in this specific cohort. Do not extrapolate the Q-SYMBIO result to general-population cardiovascular prevention or to statin-myopathy management — those are separate evidence questions with separate trial bases.

Red yeast rice and "natural statin" framing. Red yeast rice contains monacolin K, which is chemically equivalent to lovastatin; in the EU, products providing 3 mg/day or more of monacolin K from red yeast rice are now subject to restricted health-claim and labeling rules. This site does not characterize red yeast rice as a supplement-aisle equivalent of prescription statins. Statin-eligible adults should discuss statin therapy with their prescribing physician, not pursue a non-standardized red-yeast-rice substitute.

Stacking & Timeline

Mechanistic pairings are plausible but rarely backed by head-to-head synergy trials; realistic timelines run from weeks (triglycerides, blood pressure) to years (cardiovascular event reduction in high-risk populations only).

Mechanistic pairs

Omega-3 + Astaxanthin · lipid-axis pair. Omega-3 reduces hepatic VLDL secretion (the TG-lowering mechanism); astaxanthin engages HDL-C modulation in the Xia 2020 meta-analysis. The lipid-profile mechanisms are complementary on different axes (TG vs HDL-C). No head-to-head clinical synergy trial.

Vitamin K2 + Vitamin D3 · calcium-routing pair (mechanism only). Vitamin D3 supports intestinal calcium absorption; K2 supports calcium routing to bone via MGP and osteocalcin. The pairing is mechanistically logical but clinical-endpoint synergy in healthy adults is not established. See /ingredients/vitamin-d3/ for the D3-specific evidence base (LeBoff 2022 VITAL fracture sub-study PMID 35939577).

Omega-3 + CoQ10 · mitochondrial-energetics pair (preclinical). Both engage mitochondrial-membrane function; the clinical-endpoint synergy literature in cardiology is limited and preliminary.

CoQ10 + standard heart-failure therapy · adjunctive pair (Q-SYMBIO specific). The Mortensen 2014 Q-SYMBIO trial (PMID 25282031) framed CoQ10 as adjunctive to guideline-directed heart-failure therapy, not as a stand-alone intervention. The clinical synergy framing in this case is regimen-specific (300 mg/day ubiquinone added to standard care for heart failure with reduced ejection fraction) and not generalizable to healthy adults. Discuss CoQ10 use in any cardiology context with your prescribing cardiologist.

Soluble fiber + omega-3 · cardiometabolic pattern pair (mechanism cluster). Reynolds 2019 (PMID 30638909) and Jovanovski 2018 (PMID 30239559) anchor the fiber side; the Wang 2023 dose-response meta (PMID 37264945) anchors the omega-3 lipid side. The mechanistic logic — fiber-adequate dietary pattern as the substrate on which higher-dose EPA+DHA lipid effects are layered — is plausible; head-to-head synergy trials in healthy adults are lacking.

When to see results — realistic timeframes

4 to 12 weeks · triglyceride reduction (omega-3). Dose-response meta-analyses (PMID 37264945) typically observe 15 to 30% triglyceride reduction by week 4 at 2 to 4 g/day EPA+DHA, with further modest reduction by week 12.

8 to 12 weeks · blood-pressure effects (omega-3). Roughly 2 to 3 mmHg systolic reduction at doses ≥2 g/day EPA+DHA over 12 weeks or longer.

12 weeks · HDL-C shift (astaxanthin). The Xia 2020 meta-analysis (PMID 32755613) pooled trials predominantly at 6 to 24 mg/day for 8 to 12 weeks.

5 years · cardiovascular event reduction (high-risk only · REDUCE-IT). The 25% major-CV-event reduction in REDUCE-IT (PMID 30415628) was observed over a median 4.9-year follow-up. Event-prevention claims require multi-year follow-up; do not promise such outcomes from shorter-term supplementation.

  • Longevity Stack — mitochondrial-antioxidant and NAD+ pathway overlap; the cardiovascular surrogate-endpoint discussion is consistent across both pages.
  • Inflammation Relief — omega-3 eicosanoid-balance mechanism is the shared anchor; the EPA-vs-DHA distinction reappears.
  • Cognitive Support — DHA is structurally essential for brain membrane composition; omega-3 cross-domain logic.
  • Senior 60+ — life-stage page where omega-3 cardiovascular and cognitive aging benefits are most directly relevant.

Deep-dive long-form evidence reading

For deep-dive narrative on cardiovascular evidence chronology and the carotenoid complement to omega-3, see the dedicated evidence articles:

Cross-reading these two evidence articles alongside this heart-health goal page builds the holistic cardiovascular evidence picture from omega-3 landmark RCTs → carotenoid adjunct framing.

Frequently Asked Questions

1. Is omega-3 cardioprotective for everyone?

No. The conditional answer matters more than the headline. In statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes plus other risk factors, 4 g/day of pure prescription EPA reduces major cardiovascular events by 25% over 5 years (REDUCE-IT PMID 30415628). In a general adult population without prior cardiovascular events, 1 g/day of mixed EPA+DHA does not reduce total major cardiovascular events (VITAL PMID 30415637). And 4 g/day of mixed EPA+DHA carboxylic-acid did not reduce events and increased atrial fibrillation risk (STRENGTH PMID 33190147). Discuss high-dose omega-3 for cardiovascular prevention with a physician.

2. How much omega-3 should I take?

For general nutrition, 250 to 500 mg/day combined EPA+DHA matches the consensus dietary intake range. For triglyceride lowering, 2 to 4 g/day EPA+DHA has dose-dependent effect (PMID 37264945). For cardiovascular event prevention in the REDUCE-IT-specific high-risk population, 4 g/day pure prescription EPA was the trial regimen. FDA guidance is ≤2 g/day EPA+DHA from supplements (total intake up to 3 g/day considered safe); the EFSA tolerable upper intake is roughly 5 g/day EPA+DHA. The atrial fibrillation signal at ≥4 g/day in mixed EPA+DHA preparations is a real consideration in some populations.

3. Does CoQ10 prevent statin myopathy?

The published trial literature on CoQ10 in statin myopathy is mixed. This page does not characterize the CoQ10 statin-myopathy evidence base as settled. Discuss any statin-myopathy management with your prescribing physician.

4. Should I take vitamin K2 with vitamin D3?

The mechanistic pairing (D3 absorption + K2 calcium routing) is logical, but clinical-endpoint synergy in healthy adults is not established. See /ingredients/vitamin-d3/ for the published D3 evidence base, including the LeBoff 2022 VITAL fracture sub-study (PMID 35939577) which found no significant fracture reduction in already-replete adults.

5. Why does this stack not include garlic, fiber, or red yeast rice?

The current asxan.ai related-ingredients list for heart health is the four shown above. Additional cardiovascular-relevant ingredients (garlic, soluble fiber, red yeast rice, magnesium) are reasonable future additions. The References & Coverage Notes section tracks these gaps.

6. What does the Q-SYMBIO trial really show about CoQ10?

The Q-SYMBIO trial (Mortensen 2014 PMID 25282031, JACC Heart Fail) randomized 420 patients with moderate-to-severe chronic heart failure (NYHA class III to IV) to 100 mg of ubiquinone three times daily or placebo, as adjunctive to guideline-directed heart-failure therapy. At 2 years, the primary composite of major adverse cardiovascular events was reduced. This is heart-failure-specific evidence — it does not establish CoQ10 as a general-population cardiovascular-prevention intervention, and it does not directly answer the statin-myopathy question. Q-SYMBIO is the single highest-quality cited trial in that mechanism cluster.

7. Why does the omega-3 dose-response matter more than the headline trials?

Because the headline trials disagree (REDUCE-IT positive, VITAL null, STRENGTH null with AF signal), the dose-response question becomes the integrating frame. Wang 2023 (PMID 37264945) is the largest dose-response meta-analysis for the lipid endpoints — confirming the triglyceride-lowering effect is robust and dose-dependent, independent of the event-prevention question. Reading the headline trials alone tells you "it depends on population and form"; reading the dose-response meta tells you "the lipid mechanism is robust, the clinical event-prevention question is conditional."

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

  1. PMID 30415628 · Bhatt DL et al. (2019) · REDUCE-IT · NEJM · 4 g/day pure prescription EPA · primary CV composite −25% (HR 0.75) in statin-treated, elevated-TG, high-risk adults
  2. PMID 30415637 · Manson JE et al. (2019) · VITAL · NEJM · 1 g/day EPA+DHA · primary CV composite null (HR 0.92); secondary MI reduced
  3. PMID 33190147 · Nicholls SJ et al. (2020) · STRENGTH · JAMA · 4 g/day EPA+DHA carboxylic acid · primary null + atrial fibrillation HR ~1.69
  4. PMID 37264945 · Wang 2023 · triglyceride dose-response meta-analysis · 2–4 g/day EPA+DHA → 15–30% serum triglyceride reduction
  5. PMID 32755613 · Xia 2020 · astaxanthin cardiovascular meta-analysis · HDL-C significant · BMI/body-weight null
  6. PMID 37051124 · Heidari 2023 · astaxanthin CAD RCT (n=50, 12 mg/day, 8 wk) · total cholesterol significant · TNF-α / SIRT1 null
  7. PMID 39568140 · Gonzalez 2024 · astaxanthin firefighter crossover RCT (n=15, 12 mg/day, 4 wk) · oxidative/lipid/tactical outcomes non-significant
  8. PMID 25282031 · Mortensen 2014 · Q-SYMBIO · JACC Heart Fail · 300 mg/day ubiquinone adjunctive in moderate-to-severe chronic heart failure · MACE composite reduced at 2 y
  9. PMID 35939577 · LeBoff 2022 · VITAL fracture sub-study · NEJM · no significant fracture reduction in already-replete adults (vitamin D3 cross-reference)
  10. PMID 30638909 · Reynolds 2019 · dietary fiber and cardiometabolic outcomes · Lancet systematic review (cross-link context)
  11. PMID 30239559 · Jovanovski 2018 · psyllium LDL-C meta-analysis · ~0.33 mmol/L reduction at ~10.2 g/day (cross-link context)

Coverage Notes

This Heart Health page draws from four linked ingredient pages (omega-3, astaxanthin, CoQ10, Vitamin K2). The omega-3 and astaxanthin evidence is carried by full PMID citations; for CoQ10 and Vitamin K2 the cardiovascular evidence is described qualitatively as preliminary / emerging in the evidence stack and treated as mechanism candidates in How It Works, with the single heart-failure-specific Q-SYMBIO trial (PMID 25282031) cited where applicable rather than generalized. Additional cardiovascular-relevant ingredients (garlic, soluble fiber, red yeast rice, magnesium) are not currently in the related-ingredients list and are reasonable future additions. Regulatory note: FDA omega-3 supplement guidance is ≤2 g/day EPA+DHA from supplements, with total intake up to 3 g/day considered safe.

← Home

Ask Agent Axor